RT Journal Article
SR Electronic
T1 Genetic risk score for ovarian cancer based on chromosomal-scale length variation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.18.20156976
DO 10.1101/2020.07.18.20156976
A1 Chris Toh
A1 James P. Brody
YR 2020
UL http://medrxiv.org/content/early/2020/07/21/2020.07.18.20156976.abstract
AB Introduction Twin studies indicate that a substantial fraction of ovarian cancers should be predictable from genetic testing. Genetic risk scores can stratify women into different classes of risk. Higher risk women can be treated or screened for ovarian cancer, which should reduce overall death rates due to ovarian cancer. However, current ovarian cancer genetic risk scores, based on SNPs, do not work that well. We developed a genetic risk score based on structural variation, quantified by variations in the length of chromosomes.Methods We evaluated this genetic risk score using data collected by The Cancer Genome Atlas. From this dataset, we synthesized a dataset of 414 women who had ovarian serous carcinoma and 4225 women who had no form of ovarian cancer. We characterized each woman by 22 numbers, representing the length of each chromosome in their germ line DNA. We used a gradient boosting machine, a machine learning algorithm, to build a classifier that can predict whether a woman had been diagnosed with ovarian cancer in this dataset.Results The genetic risk score based on chromosomal-scale length variation could stratify women such that the highest 20% had a 160x risk (95% confidence interval 50x-450x) compared to the lowest 20%. The genetic risk score we developed had an area under the curve of the receiver operating characteristic curve of 0.88 (estimated 95% confidence interval 0.86-0.91).Conclusion A genetic risk score based on chromosomal-scale length variation of germ line DNA provides an effective means of predicting whether or not a woman will develop ovarian cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research involves analysis of de-identified data initially collected by The Cancer Genome Atlas Program. The UC Irvine Institutional Review Board reviewed this research and found that it is exempt since the research does not involve identifiable private information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe results published here are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.